Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nycomed/Diatide Will Promote NeoTect As Less Invasive Than Lung Biopsy

Executive Summary

Nycomed Amersham and marketing partner Diatide will promote NeoTect as a less invasive means of distinguishing malignant from benign lung mass compared to needle biopsy and lung surgery, which are more painful and produce higher rates of complications compared to NeoTect, the companies said.
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS034645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel